Philips resolved the Respironics litigation, settling for $1.1 billion. And Exor decided to boost its stake in the company. Supportive shareholders' remuneration is linked to Exor's portfolio results, ...
Exor grew NAV per share despite sector headwinds, strengthened its cash position, and has a low leverage ratio. Lingotto delivered strong returns, recent IPOs and asset disposals enhanced flexibility, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback